Sep 07, 2017
Two ongoing CAR-T Phase I trials of Cellectis drug candidate has been put on hold by FDA after a patient’s death FDA has put two CAR-T trials on hold following a patient’s death, less than a week after the first ever CAR-T was approved by the US regulatory agency. The patient (78) was suffering from r...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
Newsletter/Whitepaper